(NASDAQ: MXCT) Maxcyte's forecast annual revenue growth rate of 12.23% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.13%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.67%.
Maxcyte's revenue in 2025 is $34,419,000.On average, 9 Wall Street analysts forecast MXCT's revenue for 2025 to be $3,869,599,749, with the lowest MXCT revenue forecast at $3,612,622,057, and the highest MXCT revenue forecast at $4,043,478,387. On average, 9 Wall Street analysts forecast MXCT's revenue for 2026 to be $4,283,281,564, with the lowest MXCT revenue forecast at $3,920,269,904, and the highest MXCT revenue forecast at $4,805,130,825.
In 2027, MXCT is forecast to generate $5,337,967,510 in revenue, with the lowest revenue forecast at $4,599,783,354 and the highest revenue forecast at $5,745,995,603.